Management of patients with pulmonary arterial hypertension against systemic sclerodermia (part 2).
DOI:
https://doi.org/10.26641/2307-0404.2018.4.152993Keywords:
pulmonary arterial hypertension, systemic scleroderma, pharmacological treatment of pulmonary hypertensionAbstract
Pulmonary arterial hypertension (PAH) is a serious condition caused by the damage of the small pulmonary vessels, leading to the increase of pulmonary artery pressure, pulmonary vascular resistance, development of right ventricular failure and death. PAH is one of the actual problems of modern medicine due to low survival rate, rapid disability of the patients and a high cost of treatment. PAH is one of the leading causes of death in systemic sclerodermia (SSD). PAH associated with scleroderma is a unique phenotype combining the manifestations of both SSD and PAH, the pathogenetic mechanisms of which modify the clinical picture and the course of these conditions. Timely diagnosis and treatment of PAH show significant effect on survival rates, however, early detection of PAH is still difficult in SSD due to several factors. The main causes are restriction of modern screening methods and polyorganic involvement in SSD. In comparison with other subgroups of PAH the patients with SSD-PAH poorly answer to the specific PAH therapy. SSD-PAH, along with idiopathic pulmonary hypertension (IPAH), belongs to group I of pulmonary hypertension classification and according to modern consensus has a similar pathogenesis and clinical picture, however, differences in the response to therapy are observed in these groups, that indicates the role of other pathobiological mechanisms. Recent investigations explain these differences by such factors as autoimmune and inflammatory responses, more severe vascular remodeling and direct myocardial damage in the SSD. Drug therapy of PH in SSD is similar to that in IPAH and includes prostaglandins, endothelin receptor antagonists, calcium channel blockers, which are prescribed in cases of a positive vasoreactive test, PDE-5 inhibitors. In this literature review we showed traditional and new methods of PAH treatment and their relevance to SSD-PAH in accordance with randomized clinical trials.
References
McLaughlin VV, Archer SL, Badesch DB. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J. Am. Coll. Cardiol. 2009;53(17):1573-1619. PM ID: 19389575.
MathaiSC, Girgis RE, Fisher MR. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. Eur Respir J. 2007;29(3):469-75.
Simonneau G, Rubin LJ, Galie N. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med. 2008;149(8):521-30.
Galie N, Barbera JA, Frost A. AMBITION: a randomised, multicenter study of first-line ambrisentan and tadalafil combination therapy in subjects with pulmonary arterial hypertension (PAH). Eur Respir J. 2014;44:134-9.
Galie N, Olschewski H, Oudiz RJ. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2 / Circulation. 2008;117(23):3010-9.
Galie N, Badesch D, Oudiz R. Ambrisentan therapy for pulmonary arterial hypertension. J. Am. Coll. Cardiol. 2005;46(3):529-35.
McLaughlin V, Channick RN, Ghofrani HA. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. Eur Respir J. 2015;46:405-13.
Paul GA, Gibbs JS, Boobis AR. Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br J Clin Pharmacol. 2005;60(1):107-12.
Denton CP, Humbert M, Rubin L, Black CM. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis. 2006;65(10):1336-40.
Hoeper MM, Faulenbach C, Golpon H. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur. Respir. J. 2004;24(6):1007-10.
Dardi F, Manes A, Palazzini M. Combining bosentan and sildenafil in pulmonary arterial hypertension patients failing monotherapy: real-world insights. Eur Respir J. 2015;46:414-21.
Hoeper MM, Leuchte H, Halank M. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J. 2006;28(4):691-4.
Simonneau G, Barst RJ, Galie N. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002;165(6):800-4.
Johnson SR,BrodeSK, Mielniczuk LM, Granton JT. Dual therapy in IPAH and SSc-PAH. A qualitative systematic review. Respir Med. 2012;106:730-9.
Avouac J, Wipff J, Kahan A. Effects of oral treatments on exercise capacity in systemic sclerosis related pulmonary arterial hypertension: a meta-analysis of randomised controlled trials. Ann Rheum Dis. 2008;67:808-14.
Galiè N, Humbert M, Vachiery JL. ESC/ERS guidelines 2015for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37:67-119.
Grimminger F., Weimann G, Frey R. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J. 2009;33(4):785-92.
Ghofrani HA, Grimminger F. Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension. Eur Respir Rev. 2009;18:35-41.
Pietra GG, Edwards WD, Kay JM. Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. Circulation. 1989;80(5):1198-206.
Ghofrani HA, Morrell NW, Hoeper MM. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am. J. Respir. Crit. Care Med. 2010;182(9):1171-7.
Sanchez O, Sitbon O, Jais X. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest. 2006;130(1):182-9.
Aguero J, Hadri L, Hammoudi N. Inhaled Gene Transfer for Pulmonary Circulation. Methods Mol Biol. 2017;1521:339-49. doi: 10.1007/978-1-4939-6588-5_24
Orens JB, Estenne M, Arcasoy S. International guidelines for the selection of lung transplant candidates: 2006 update – a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2006;25(7):745-55.
Keogh AM, Mayer E, Benza RL. Interventional and surgical modalities of treatment in pulmonary hypertension. J Am Coll Cardiol. 2009;54(1):67-77.
Kowal-Bielecka O, Fransen J, Avouac J. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327-39. doi: 10.1136/annrheumdis-2016-209909.
Vonk MC, Marjanovic Z, van den Hoogen FH, et al. Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis. Ann Rheum Dis. 2008;67(1):98-104.
Girgis RE,MathaiSC, Krishnan JA. Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases. J Heart Lung Transplant. 2005;24(10):1626-31.
Sitbon O, Humbert M, Jais X. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005;111(23):3105-11.
MacDonald SL,RubensMB, Hansell DM. Nonspecific interstitial pneumonia and usual interstitial pneumonia: comparative appearances at and diagnostic accuracy of thin-section CT. Radiology. 2001;221(3):600-5.
Stamm JA, Risbano MG, Mathier MA. Overview of current therapeutic approaches for pulmonary hypertension. Pulm Circ. 2011;1(2):138-159. doi: 10.4103/2045-8932.83444
Overbeek MJ, van Nieuw Amerongen GP, Boonstra A. Possible role of imatinib in clinical pulmonary veno-occlusive disease. Eur. Respir. J. 2008;32(1):232-5.
Ngian GS, Stevens W, Prior D. Predictors of mortality in connective tissue disease-associated pulmonary arterial hypertension: a cohort study. Arthritis Res Ther. 2012;14:213
McLaughlin VV, Oudiz RJ, Frost A. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006;174(11):1257-63.
Vane JR, Anggard EE, Botting RM. Regulatory functions of the vascular endothelium. N Engl J Med. 1990;323(1):27-36.
Ghofrani HA, Voswinckel R, Gall H, et al. Riociguat for pulmonary hypertension. Future Cardiol. 2010;6(2):155-66.
Ghofrani HA, D’Armini AM, Grimminger F. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013;369:319-29.
Rituximab for Scleroderma-Associated Pulmonary Arterial Hypertension. Available from: https://sclerodermanews.com/rituximab-for-scleroderma-associated-pulmonary-arterial hypertension
Said K. Macitentan in pulmonary arterial hypertension: The SERAPHIN trial.Glob Cardiol Sci Pract. 2014;2014(2):26-30. doi: 10.5339/gcsp.2014.20
Freyhaus H Ten, Dumitrescu D, Bovenschulte H. Significant improvement of right ventricular function by imatinib mesylate in scleroderma-associated pulmonary arterial hypertension. Clin. Res. Cardiol. 2009;98(4):265-7.
Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch DN. Sildenafil citrate therapy for pulmonary arterial hypertension. Engl J Med. 2005;353(20):2148-57.
Keogh A, Strange G, Kotlyar E. Survival after the initiation of combination therapy in patients with pulmonary arterial hypertension: an Australian collaborative report. Intern Med J. 2011;41:235-44.
Bernstein EJ, Peterson ER, Sell JL. Survival of adults with systemic sclerosis following lung transplantation: a nationwide cohort study. Arthritis Rheumatol. 2015;67(5):1314-22.
Galie N, Brundage BH, Ghofrani HA. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009;119(22):2894-903.
Boucherat O, Vitry G, Trinh I. The cancer theory of pulmonary arterial hypertension. Pulm Circ. 2017;7(2):285-299. doi: 10.1177/2045893217701438
Reich N, Maurer B, Akhmetshina A. The transcription factor Fra-2 regulates the production of extracellular matrix in systemic sclerosis. Arthritis Rheum. 2010;62(1):280-90.
Maurer B, Busch N, Jungel A. Transcription factor fos-related antigen-2 induces progressive peripheral vasculopathy in mice closely resembling human systemic sclerosis. Circulation. 2009;120(23):2367-76.
Galie N, Corris PA, Frost A. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol. 2013;62(25):60-72.
DentonCP, Pope JE, Peter HH. Use in PAH associated with Scleroderma and ConnectiveTissue Diseases (TRUST) Investigators. Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. Ann Rheum Dis. 2008;67(9):1222-8.
Jing ZC, Yu ZX, Shen JY, Wu BX. Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. Am J Respir Crit Care Med. 2011;183:1723-9.
Downloads
How to Cite
Issue
Section
License
Copyright (c) 2018 Medicni perspektivi (Medical perspectives)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submitting manuscript to the journal "Medicni perspektivi" the author(s) agree with transferring copyright from the author(s) to publisher (including photos, figures, tables, etc.) editor, reproducing materials of the manuscript in the journal, Internet, translation into other languages, export and import of the issue with the author’s article, spreading without limitation of their period of validity both on the territory of Ukraine and other countries. This and other mutual duties of the author and all co-authors separately and editorial board are secured by written agreement by special form to use the article, the sample of which is presented on the site.
Author signs a written agreement and sends it to Editorial Board simultaneously with submission of the manuscript.
